ArGEN-X appoints Werner Lanthaler to its Supervisory Board


He has been Chief Executive of Evotec for the past five years

ArGEN-X, a clinical stage human therapeutic antibody company based in Belgium, has appointed Werner Lanthaler to its Supervisory Board.

Lanthaler is currently Chief Executive of Evotec, a role he took in March 2009. Under his leadership Evotec has become a leading drug discovery research organisation.

Before that, he spent nine years as Chief Financial Officer at Intercell (2000-2009). During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine and antibody player.

Sign up for your free email newsletter

From 1998 to 2000, Lanthaler was Director of the Federation of Austrian Industry, and from 1995 to 1998 he was a Senior Management Consultant at McKinsey & Company.